Alberto Puccini

List of Publications by Citations

80 papers	1,245 citations	16 h-index	35 g-index
89 ext. papers	1,915 ext. citations	5.8 avg, IF	4.66 L-index

#	Paper	IF	Citations
80	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. *Cancer Treatment Reviews*, **2018**, 63, 40-47	14.4	433
79	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. *Molecular Cancer Research*, **2018**, 16, 805-812	6.6	114
78	Outlooks on Epstein-Barr virus associated gastric cancer. *Cancer Treatment Reviews*, **2018**, 66, 15-22	14.4	74
77	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. *Oncologist*, **2018**, 23, 1319-1327	5.7	61
76	B cell and B cell-related pathways for novel cancer treatments. *Cancer Treatment Reviews*, **2019**, 73, 10-19	14.4	59
75	Safety and Tolerability of c-MET Inhibitors in Cancer. *Drug Safety*, **2019**, 42, 211-233	5.1	40
74	Colorectal cancer: epigenetic alterations and their clinical implications. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 439-448	11.2	35
73	Molecular profile of BRCA-mutated biliary tract cancers. *ESMO Open*, **2020**, 5, e000682	6	34
72	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. *Cancer Cell International*, **2018**, 18, 99	6.4	34
71	Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. *International Journal of Cancer*, **2020**, 147, 2948-2956	7.5	32
70	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. *Clinical Cancer Research*, **2019**, 25, 3096-3103	12.9	30
69	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. *Expert Review of Anticancer Therapy*, **2018**, 18, 251-266	3.5	29
68	What We Know About Stage II and III Colon Cancer: It's Still Not Enough. *Targeted Oncology*, **2017**, 12, 265-275	5	21
67	Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting. *Nature Reviews Clinical Oncology*, **2018**, 15, 77-78	19.4	20
66	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. *Oncologist*, **2019**, 24, 319-326	5.7	19
65	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). *Clinical Cancer Research*, **2020**, 26, 5943-5951	12.9	17
64	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies **2020**, 8,		15

63	The impact of panitumumab treatment on survival and quality of life in patients with wild-type metastatic colorectal cancer. *Cancer Management and Research*, **2019**, 11, 5911-5924	3.6	15
62	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. *Clinical Cancer Research*, **2018**, 24, 784-793	12.9	14
61	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. *Oncologist*, **2020**, 25, 404-413	5.7	13
60	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. *European Journal of Cancer*, **2020**, 140, 119-129	7.5	13
59	Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. *ESMO Open*, **2020**, 5, e000942	6	11
58	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. *Clinical Colorectal Cancer*, **2019**, 18, e8-e19	3.8	9
57	The urgent need to improve the tools to assess clinical benefit and value of cancer treatment. *European Journal of Cancer*, **2017**, 83, 324-328	7.5	8
56	Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).. *Journal of Clinical Oncology*, **2019**, 37, 4085-4085	2.2	8
55	Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.. *Journal of Clinical Oncology*, **2019**, 37, 4133-4133	2.2	8
54	Management of Advanced Small Bowel Cancer. *Current Treatment Options in Oncology*, **2018**, 19, 69	5.4	8
53	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. *Cancers*, **2020**, 12,	6.6	7
52	A new prognostic and predictive tool for shared decision making in stage III colon cancer. *European Journal of Cancer*, **2020**, 138, 182-188	7.5	7
51	Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC).. *Journal of Clinical Oncology*, **2020**, 38, 479-479	2.2	6
50	Maintenance Olaparib for Metastatic Pancreatic Cancer. *New England Journal of Medicine*, **2019**, 381, 1491	59.2	4
49	Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low. *Annals of Oncology*, **2018**, 29, viii650-viii651	10.3	4
48	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. *European Journal of Cancer*, **2019**, 111, 138-147	7.5	3
47	Redefining Colorectal Cancer by Tumor Biology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 1-13	7.1	3
46	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. *European Journal of Cancer*, **2020**, 131, 89-97	7.5	3

45	Molecular Variances Between Right- and Left-sided Colon Cancers. *Current Colorectal Cancer Reports*, **2018**, 14, 152-158	1	3
44	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. *Clinical Colorectal Cancer*, **2018**, 17, 215-222.e3	3.8	3
43	Molecular landscape of colorectal cancers harboring R-spondin fusions.. *Journal of Clinical Oncology* , **2019**, 37, 3588-3588	2.2	3
42	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. *Journal of Clinical Oncology*, **2019**, 37, 606-606	2.2	3
41	Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. *Frontiers in Oncology*, **2021**, 11, 662055	5.3	3
40	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2018**, 36, 12106-12106	2.2	2
39	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. *Journal of Clinical Oncology*, **2019**, 37, 3145-3145	2.2	2
38	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. *Journal of Cancer Metastasis and Treatment*, **2018**, 4,	3.8	2
37	Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. *JCO Precision Oncology*, **2022**, 6, e2100245	3.6	2
36	Young Patients with Colorectal Cancer: Risk, Screening, and Treatment. *Current Colorectal Cancer Reports*, **2018**, 14, 159-165	1	1
35	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. *Journal of Clinical Oncology*, **2018**, 36, 3576-3576	2.2	1
34	Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.. *Journal of Clinical Oncology*, **2018**, 36, 645-645	2.2	1
33	Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, 3600-3600	2.2	1
32	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. *Npj Precision Oncology*, **2021**, 5, 95	9.8	1
31	Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer. *Oncologist*, **2021**, 26, e1730-e1741	5.7	1
30	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.. *Cancers*, **2022**, 14,	6.6	1
29	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. *International Journal of Cancer*, **2019**, 145, 2082-2090	7.5	0
28	Metastatic sarcoma: tailored strategies for a heterogeneous disease. *Memo - Magazine of European Medical Oncology*, **2020**, 13, 179-184	0.3	0

27	Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.. *Journal of Clinical Oncology*, **2019**, 37, 3595-3595	2.2	0
26	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. *Journal of Clinical Oncology*, **2019**, 37, 3048-3048	2.2	0
25	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. *Journal of Clinical Oncology*, **2020**, 38, 245-245	2.2	0
24	Microsatellite-Instability-High Advanced Colorectal Cancer. *New England Journal of Medicine*, **2021**, 384, 971-972	59.2	0
23	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. *Scientific Reports*, **2021**, 11, 12191	4.9	0
22	Association of genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II and III colon cancer.. *Journal of Clinical Oncology*, **2018**, 36, 626-626	2.2	
21	Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas.. *Journal of Clinical Oncology*, **2018**, 36, 60-60	2.2	
20	The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.. *Journal of Clinical Oncology*, **2018**, 36, 651-651	2.2	
19	Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.. *Journal of Clinical Oncology*, **2018**, 36, 662-662	2.2	
18	Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.. *Journal of Clinical Oncology*, **2018**, 36, 646-646	2.2	
17	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2018**, 36, 12098-12098	2.2	
16	Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2018**, 36, 3577-3577	2.2	
15	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. *Journal of Clinical Oncology*, **2018**, 36, 3611-3611	2.2	
14	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. *Journal of Clinical Oncology*, **2018**, 36, 4098-4098	2.2	
13	Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.. *Journal of Clinical Oncology*, **2018**, 36, 12107-12107	2.2	
12	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. *Journal of Clinical Oncology*, **2018**, 36, e15578-e15578	2.2	
11	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. *Journal of Clinical Oncology*, **2019**, 37, 594-594	2.2	
10	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. *Journal of Clinical Oncology*, **2019**, 37, 564-564	2.2	

9	Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. *Journal of Clinical Oncology*, **2019**, 37, 566-566	2.2
8	Streamlining universal screening for lynch syndrome (LS): Towards improved yield of genetic counseling (GC).. *Journal of Clinical Oncology*, **2019**, 37, 503-503	2.2
7	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. *Journal of Clinical Oncology*, **2019**, 37, 558-558	2.2
6	Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.. *Journal of Clinical Oncology*, **2019**, 37, 63-63	2.2
5	Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2019**, 37, 3130-3130	2.2
4	Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.. *Journal of Clinical Oncology*, **2019**, 37, 2633-2633	2.2
3	Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer.. *Journal of Clinical Oncology*, **2020**, 38, 227-227	2.2
2	Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. *Journal of Clinical Oncology*, **2020**, 38, 190-190	2.2
1	Comprehensive gene expression analysis of IDH1/2 mutant biliary cancers (BC).. *Journal of Clinical Oncology*, **2020**, 38, 4598-4598	2.2